Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bcff13f8573db698307f919e6385d5c4 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2800-782 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-671 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-327 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-65 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-67 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-443 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-38 |
filingDate |
2005-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2007-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57137dd4780e2d84622549fce24a94ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bd6abba2369be6d68f1cee60d93376e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a06367da42691ba1cc2d94fece89deb7 |
publicationDate |
2007-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-7268148-B2 |
titleOfInvention |
Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
abstract |
Acne-affected skin has been found to be accompanied by the presence of matrix-degrading enzymes such as MMPs and neutrophil elastase, induction of neutrophils, and a reduction in procollagen biosynthesis. This invention treats scarring and inflammation accompanying acne by administering, topically or systemically, at least one of (i) an inhibitor of the matrix degrading enzymes and (ii) a cytokine inhibitor that alleviates inflammation and thus also alleviate neutrophil infiltration. Alleviating the matrix degradation and renormalizing procollagen biosynthesis allows for reduced inflammation and better natural repair of acne-affected skin. Inhibiting cytokines alleviates induction of MMPs in resident skin cells, and also alleviates inflammation with its concommitant induction of neutrophils from the blood stream bringing MMPs and elastase into the acne lesion. Dimishing the presence of matrix-degrading enzymes in the acne lesion reduces imperfect repair of the skin and thus decreases scarring in acne-affected skin. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11013730-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10058542-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1994923-A2 |
priorityDate |
1999-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |